In the largest ovarian cancer trial to date, annual screening reduced mortality by 20%, but the authors and others caution that longer follow-up is needed to assess efficacy and cost-effectiveness.
Medscape Medical News …read more
In the largest ovarian cancer trial to date, annual screening reduced mortality by 20%, but the authors and others caution that longer follow-up is needed to assess efficacy and cost-effectiveness.
Medscape Medical News …read more